
Seven & i Holdings to Reject $47B Couche Tard Bid, Eyes Independent Growth
Mar 04, 2025 03:05 am UTC| Business
Seven i Holdings Co., Ltd. (TYO:3382) is reportedly set to reject a $47 billion acquisition offer from Canadas Alimentation Couche Tard Inc. (TSX:ATD), according to Japans Yomiuri newspaper. The retail giant, best known...

CoreWeave Files for IPO, Eyes $35B+ Valuation Amid AI Boom
Mar 04, 2025 03:05 am UTC| Technology Business
CoreWeave, a cloud provider backed by Nvidia (NASDAQ:NVDA), has filed for a U.S. IPO, aiming for a valuation exceeding $35 billion. The company, which supplies high-powered chips and data center access for AI workloads,...

TSMC to Invest $100 Billion in U.S. Chip Manufacturing, Expanding Arizona Operations
Mar 04, 2025 03:05 am UTC| Technology Business
Taiwan Semiconductor Manufacturing (NYSE:TSM) has announced a $100 billion investment in U.S. chip-making facilities over the next four years, expanding its presence in Arizona. The company plans to construct three new...

Norwegian Air to Save Millions with Boeing 737-800 Purchase
Mar 03, 2025 09:29 am UTC| Business
Budget airline Norwegian has announced its plan to acquire 10 Boeing (NYSE:BA) 737-800 aircraft from its leased fleet, aiming to cut costs and enhance flexibility. The transaction, set to close in Q1, will be initially...

Trump Weighs Final Tariff Decision on Canada, Mexico, and China
Mar 03, 2025 09:29 am UTC| Politics Business
U.S. Commerce Secretary Howard Lutnick announced on Sunday that tariffs on Mexico and Canada will take effect on Tuesday, though President Donald Trump will determine whether to impose the full 25% rate. Speaking on Fox...

FDA Reviews GSK’s Depemokimab for Asthma and CRSwNP Treatment
Mar 03, 2025 09:29 am UTC| Business Governance Health
The U.S. Food and Drug Administration (FDA) has accepted GlaxoSmithKlines (NYSE:GSK) biologics license application for depemokimab, an ultra-long-acting monoclonal antibody targeting interleukin-5 (IL-5). The drug is under...

Intuit (INTU) Poised for 25% Upside, Mizuho Raises Price Target
Mar 03, 2025 09:29 am UTC| Business
Intuit Inc. (NASDAQ: INTU) remains undervalued despite recent stock gains, with Mizuho analysts projecting a 25% upside. The brokerage reiterated its Outperform rating and raised its price target to $765 from $750, citing...